Results 1 to 10 of about 2,093 (154)

Enhancement of retinal Müller glia’s phagocytic activity against hard exudates by conbercept via activation of PPARγ-CD36 axis in diabetic retinopathy [PDF]

International Journal of Ophthalmology
AIM: To investigate the effects and the underlying mechanism(s) of conbercept on the phagocytosis of hard exudates (HEs) by Müller glia in diabetic retinopathy (DR).
Ying-Ying Zhu, Shi-Yue Qin, Hai Xie, Yin-Ping Liu, Xiao-Sa Li, Chao-Yang Zhang, Yan-Chun Zhang, Jing-Fa Zhang   +7 more
doaj   +3 more sources

Effect and factors associated with reactivation after intravitreal conbercept or aflibercept in retinopathy of prematurity [PDF]

European Journal of Medical Research
Background To evaluate the effect and factors associated with the reactivation of retinopathy of prematurity (ROP) after intravitreal conbercept or aflibercept.
Chunling Huang, Weikang Zou, Wenbei Ma, Jiali Li, Yichen Bai, Rong Wu, Qiqi Li, Qi Fang, Wenna Chen, Xiaohe Lu, Songfu Feng   +10 more
doaj   +3 more sources

Efficacy of Intravitreal Conbercept in Vitrectomy for Proliferative Diabetic Retinopathy: An Integrated Meta-Analysis and Bibliometric Study [PDF]

Clinical Ophthalmology
Guangda Li,1,* Mingxuan Zhang,2,* Yifeng Ke,2 Chuanzhen Zheng,3 Liangzhang Tan,2 Yongtao Li,2 Emmanuel Eric Pazo,2 Chunli Chen,4 Xinjun Ren2 1Department of Ophthalmology, Linyi People’ s Hospital, Linyi, Shandong, People’s Republic of ...
Li G, Zhang M, Ke Y, Zheng C, Tan L, Li Y, Pazo EE, Chen C, Ren X   +8 more
doaj   +3 more sources

Ocular pharmacokinetics of intravitreal conbercept in a rabbit model following retinal scatter laser photocoagulation [PDF]

Frontiers in Pharmacology
ObjectiveThe present study aims to evaluate the ocular pharmacokinetics of intravitreal conbercept after retinal scatter laser photocoagulation.MethodsThirty male Chinchilla rabbits (60 eyes) were used in this study.
Lanlan Chen, Lanlan Chen, Hua Liu, Hua Liu, Qingrong Zhang, Qingrong Zhang, Houbin Huang   +6 more
doaj   +3 more sources

Recent advances in the study of Conbercept for diabetic macular edema [PDF]

International Journal of Retina and Vitreous
Diabetic macular edema (DME) is one of the leading causes of blindness in diabetic retinopathy. As a domestically developed fusion protein drug in China, the anti-vascular endothelial growth factor (VEGF) agent Conbercept has demonstrated significant ...
Zhe Liu, Xin Zheng, Hong Li
doaj   +3 more sources

Conbercept combined with 577 nm subthreshold micropulse laser for diabetic macular edema [PDF]

International Journal of Ophthalmology
AIM: To evaluate the efficacy and safety of conbercept combined with 577 nm subthreshold micropulse laser (STML) for treatment of diabetic macular edema (DME). METHODS: A retrospective study was conducted.
Ying Han, Ming-Yuan Yang, Han-Lin Wang, Jia Meng, Mei-Lin Zhu, Si-Yu Ma, Shi-Han Wang, Xiu-Juan Li   +7 more
doaj   +3 more sources

Comparison of ranibizumab and conbercept treatment in type 1 prethreshold retinopathy of prematurity in zone II. [PDF]

BMC Pediatr
The treatment with anti-VEGF for Retinopathy of prematurity (ROP) has already been widely applied in clinics even though there are still many concerns about this treatment.
Yang XM, Li QP, Wang ZH, Zhang MN.
europepmc   +4 more sources

Efficacy and safety of intravitreal conbercept and triamcinolone acetonide for wet age-related macular degeneration in China: a meta-analysis. [PDF]

Int Ophthalmol
Several studies have investigated the efficacy and safety of Conbercept versus Triamcinolone acetonide for the treatment of wet age-related macular degeneration (wAMD), but the results are controversial. Therefore, this meta-analysis aims to evaluate the
Yang F, Hu R.
europepmc   +4 more sources

Combined treatment of submacular hemorrhage with low-dose subretinal recombinant tissue plasminogen activator and intravitreal conbercept. [PDF]

BMC Ophthalmol
Pars Plana Vitrectomy (PPV) combined with subretinal injection of low-dose recombinant tissue plasminogen activator (rt-PA) and intravitreal injection of Conbercept as a novel therapy for submacular hemorrhage (SMH) requires evaluation.
Ma Y, Rao S, Tan Y, Du H, Sun X.
europepmc   +3 more sources

Comparative study on the efficacy of Conbercept and Aflibercept in the treatment of neovascular age-related macular degeneration [PDF]

Scientific Reports
This study compares the effectiveness of Conbercept and Aflibercept in treating neovascular age-related macular degeneration (nAMD). Conducted at the First Affiliated Hospital of Chongqing Medical University's Ophthalmology Department (May 2020–May 2023),
Hao Xie, Huan Ju, Jing Lu, Xing Wang, Hui Peng   +4 more
doaj   +3 more sources